MedMira receives Health Canada approval for its Multiplo® Rapid (TP/HIV) Test for Syphilis and HIV

Halifax, Nova Scotia – December 24, 2024 – MedMira Inc. (MedMira) (TSXV: MIR) announced today that it has received today, on December 24, 2024, the approval from Health Canada for its Multiplo® Rapid TP/HIV Test (Multiplo® TP/HIV) to be rolled out across Canada, a critical point-of-care tool to address the health crises with HIV and […]
MedMira receives CE mark for its VYRA™ CoV2Flu Antigen Test

Halifax, Nova Scotia, 11 January, 2023 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the receipt of the CE mark for its VYRA™ CoV2Flu Antigen Test (VYRA™ CoV2Flu), the fastest combination antigen test available to detect SARS-CoV-2, Flu A and Flu B. The Company received the CE mark and VYRA™ CoV2Flu is now available in […]
MedMira Introduces VYRA TriDemic

Halifax, Nova Scotia, 29 December, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) presents its latest addition to the VYRA™ product line, the VYRA™ TriDemic Antigen Rapid Test for the simultaneous detection of SARS-CoV-2, Flu A, Flu B and Respiratory Syncytial Virus (RSV). VYRA™ TriDemic, a four-in-one test, which is a direct response to the […]
MedMira’s Multiplo TP/HIV Rapid Test: One Test, More Answers

A study completed by the Indian Red Cross Blood Society showed that MedMira’s Multiplo® TP/HIV Rapid Test is your immediate quality answer. MedMira’s Multiplo® TP/HIV Rapid Test. One Test, More Answers. Human immunodeficiency virus (HIV) is a blood-borne virus that poses a significant threat to global health, especially given that current therapies for HIV infection […]